WYWannian Yan

Wannian Yan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wannian Yan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Digital Counting of Quantum Dots Nanobeads on Lateral Flow Test Strips Enables Ultrasensitive Point-of-Care Diagnostics

    by Wannian Yan, Wenwen Xia, Qinglei Hu, Shaoqun Zeng, Huanxing Han, Pengfei Zhang

    Lateral flow assay (LFA) is a versatile platform for the rapid detection of various pathogens, pollutants, and toxins at point of care (POC). However, a traditional lateral flow assay strip is still not sensitive enough for early detection of disease, and previous works to enhance the sensitivity of LFA systems have suffered from additional signal amplification chemistry, tedious operation procedure, or expensive signal amplification instruments. In this study, we introduced a digital counting strategy for signal measurement to improve the detection sensitivity of quantum dot nanobead-based lateral flow immunoassays, offering an alternative to traditional fluorescence intensity-based quantification. The ultrasensitive single-molecule POC detection system is composed of an ultrabright fluorescent quantum dot nanobead-based lateral flow assay strip and a portable fluorescent microscopy reader for numerating single immunocomplexes on a test line. As a proof-of-concept, we performed digital LFA to detect interleukin-6 in 1% BSA with LoD as low as 0.02 pg/mL, which is ∼100 times more sensitive than analog LFA. Moreover, an amplification-free assay for HIV RNA was also demonstrated by combining CRISPR-Cas13 reaction and digital LFA with a sensitivity of as low as 89 copies/mL. A prototype portable and affordable fluorescent microscopy reader was designed and demonstrated its ability to be used for on-site testing. All in all, the developed digital LFA system not only has single-molecule level sensitivity but also satisfies the rapidity, easy operation, portability, and low-cost requirements for POC testing.


  • Open Access

    Plasmon-Enhanced Quantum Dot Nanobeads-Based Lateral Flow Assay with Lower Background and Improved Sensitivity

    by Xiaoyi Li, Yucheng Wang, Wannian Yan, Yijie Tang, Ru-Jia Yu, Huanxing Han, Pengfei Zhang

    Developing a quantum dot (QD) nanobeads-based lateral-flow assay (LFA) is of great importance for achieving ultrasen-sitive, quantitative, and rapid testing of clinical specimens at the point-of-care. However, the QD nanobeads currently used in LFA still have drawbacks such as large particle size, which leads to high background, easy aggregation, and poor fluidity. To address these issues, a promising strategy is to utilize plasmonic energy transfer from gold nanoparticles (AuNPs) to QDs in order to create smaller size and brighter fluorescent QD nanobeads, without simply increasing the amount of QDs encapsulated in the nanobeads. In this study, we prepared the plasmon-enhanced quantum dot nano-beads (PEQNB) by encapsulating AuNPs and QDs into polymer nanobeads using the versatile emulsion-solvent evapora-tion method. We were able to detect as low as ~4347 PEQNBs nanoparticles using a gel imager, which is 14.6 times brighter than the QD nanobeads of a similar size. Compared to QD nanobeads of similar size, the PEQNB-based LFA for interleukin-6 detection exhibited higher fluorescent signal and lower background. The detection limit of PEQNB-based LFA was 1.63-fold higher than that of QD nanobeads. Furthermore, compared to larger-sized QD nanobeads with aver-age diameter of 131.1nm, PEQNB with average diameter of 78.6 nm based LFA exhibited similar levels of fluorescence intensity, but 1.55-fold lower background signal and 1.44-fold lower detection limits. This work demonstrates that opti-mized plasmon-enhanced QD nanobeads can further increase the sensitivity and lower the background signals of ultra-sensitive QD nanobeads-based LFA for disease diagnosis at point-of-care.

  • Open Access

    Exploration of the Potential Mechanism of the Common Differentially Expressed Genes in Psoriasis and Atopic Dermatitis

    by Zhiyu Zhou, Li Meng, Yawen Cai, Wannian Yan, Yun Bai, Jia Chen

    Backgrounds. Psoriasis and atopic dermatitis are two common chronic inflammatory skin diseases that enormously deteriorate the psycho‐physical and socio‐economic condition of the patients. Although differential immune responses have been found to operate in the pathomechanisms of atopic dermatitis and psoriasis, the epidermal keratinocytes are the major targets in both diseases, and sometimes, they show similar clinical presentations. The skin barrier, itching, and inflammation are current and future treatment targets for both of them, but the relevant shared mechanisms of the two diseases are far from understood. Methods. The differential analyses of GSE14905 (psoriasis) and GSE32924 (atopic dermatitis) deposited in GEO database were conducted and obtained their differential expressed genes. Moreover, PPI, functional modules, GO, and KEGG enrichment analyses were used for the further analysis. The mouse models of psoriasis and atopic dermatitis were established, and then, RT‐qPCR and Western blotting assay were performed to check the abundant changes of hub genes. Results. There are 732 differentially expressed genes in psoriasis versus nonlesional skin samples. Besides, 611 differentially expressed genes were identified in atopic dermatitis versus nonlesional skin data sets. Based on these differentially expressed genes, we predicted their joint and individual protein‐protein interaction networks and functional modules in both psoriasis and atopic dermatitis. Through the PPI network of genes, we calculated the hub nodes and do the GO and KEGG enrichment analysis of overlapped genes of psoriasis and atopic dermatitis, which suggested there were some terms like “positive regulation of interleukin‐12 production,” “centromeric region,” and “TNF signaling pathway.” Conclusion. We constructed the predicted PPI networks and functional modules related to psoriasis and atopic dermatitis and distinguished the key candidate target genes CXCL8, STAT1, and MMP9 in the diagnosis and therapy of similar pathogenesis.